Arkolith/Insider Trading/MREO/Form 4

Fox Christine Ann

Chief Financial OfficerMereo BioPharma Group plc (MREO) · full profile →Form 4 · filed Jun 27, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$148K
Net Open-Market Flow
-$148K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 26, 2024Sell(S)29K$3.39$100K58K
Jun 25, 2024Sell(S)13K$3.69$48K87K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-078467) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML